Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $348.98M | $14.75M | $0.15 |
| 2024 | $299.97M | $11.03M | $0.02 |
| 2023 | $256.11M | $29.95M | $0.70 |
| 2022 | $235.53M | $11.32M | $0.13 |
| 2021 | $166.12M | $210.0K | $1.64 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.21 per share
Typical surprise -111.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.05 vs $0.08miss
- Mon, May 11$-0.09 vs $0.07miss
- Mon, Mar 16$0.08 vs $0.09miss
- Thu, Nov 6$0.05 vs $0.38miss
- Thu, Aug 7$0.03 vs $0.13miss
- Thu, May 8$-0.01 vs $0.06miss
Estimates and results for OPAL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OPAL's reported EPS growth of -45.0% a year over 4 years. Historical EPS growth of -45% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.23
- Implied price
- $3.72
- Return from $2.15
- 11.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.85 — -13.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -25.0% | -7.0% | -4.1% | -1.5% | 0.8% | 3.0% |
| -20.0% | -0.8% | 2.3% | 5.0% | 7.5% | 9.8% |
| -15.0% | 5.4% | 8.7% | 11.6% | 14.3% | 16.7% |
| -10.0% | 11.6% | 15.1% | 18.2% | 21.0% | 23.6% |
| -5.0% | 17.8% | 21.4% | 24.7% | 27.7% | 30.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- Newsglobenewswire.com·2d ago·Neutral
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity • Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes
View source ↗ - Newsseekingalpha.com·5d ago·Positive
OPAL Fuels Inc. (OPAL) Q2 2026 Earnings Call Transcript OPAL Fuels Inc. (OPAL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Negative
OPAL Fuels Q2 Earnings Call Highlights OPAL Fuels NASDAQ: OPAL reported second-quarter 2026 adjusted EBITDA of $23.1 million, up 40% from the prior-year period, as production tax credits, fuel station services growth and lower general and administrative expenses helped offset flat Renewable Identification Number, or RIN, pricing.
View source ↗ - Newsbusinesswire.com·5d ago·Negative
OPAL Fuels Reports Second Quarter 2026 Results WHITE PLAINS, N.Y.--(BUSINESS WIRE)--OPAL Fuels (“OPAL Fuels” or the “Company”) (Nasdaq: OPAL) today announced financial and operating results for the three and six months ended June 30, 2026. "Second quarter financial results were solid and in line with our expectations with adjusted EBITDA growth of 40% percent over the second quarter of last year," said Adam Comora, Co-Chief Executive Officer of OPAL Fuels. "Contribution from 45Z production tax c
View source ↗